ADMA Investors Can Take Charge in Class Action Lawsuit for Securities Fraud by Rosen Law Firm

Investors Alert: Lead the ADMA Biologics Class Action

Recently, investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have been reminded of their potential to lead a class action lawsuit concerning securities fraud. This lawsuit was initiated by the reputable Rosen Law Firm, known globally for protecting investor rights. The firm has set a deadline of August 10, 2026, for investors to confirm their status as lead plaintiffs in this case.

Why Join the Class Action?

If you bought ADMA Biologics securities between August 9, 2024, and March 25, 2026, you might be entitled to compensation through a contingency fee arrangement, meaning you won't have to pay any out-of-pocket costs. The essence of the case revolves around significant disclosures that allegedly misled investors regarding the company’s business operations and internal controls.

Background of the Lawsuit

The Rosen Law Firm has observed that ADMA Biologics made critical misstatements during the class period. It is alleged that the company engaged in undisclosed related party transactions and adopted questionable practices like channel stuffing to inflate revenues. Furthermore, related internal controls were reported to be inadequate, leading to deceptive statements concerning the company’s operational health.

This lawsuit underscores the importance of ensuring transparency and honesty in corporate communications. Misleading shareholders can lead to significant financial losses, directly impacting their investment interests.

How to Participate

If you are among the affected investors, actions can be initiated by visiting rosenlegal.com/cases/adma-biologics-inc/join. You can also call Phillip Kim, Esq., at 866-767-3653 or send an email to [email protected]. Signing up is essential for those who wish to take an active role in guiding the proceedings as a lead plaintiff.

The Role of Lead Plaintiff

Serving as a lead plaintiff involves representing the class and making critical decisions about the direction of the lawsuit. It’s essential to select qualified legal counsel for this task, as many firms lack the necessary expertise or resources to manage securities class actions effectively. Rosen Law Firm has been recognized for their success in similar cases, being responsible for substantial securities class action settlements in the past.

Why Choose Rosen Law Firm?

The firm has a solid track record, having represented investors on a global scale and specializing in securities class actions. They were acknowledged for achieving the largest securities class action settlement against a Chinese company at a time. In 2019 alone, the firm managed to recover over $438 million for its investors.

Next Steps to Remember

1. Confirm your investment in ADMA Biologics within the class period mentioned above.
2. Visit the Rosen Law Firm's website for more information or to join the class action.
3. Reach out to their firm if you seek to serve as a lead plaintiff.
4. Stay informed about the developments in this case by following the law firm on platforms like LinkedIn or Twitter.

Conclusion

Participation in class action lawsuits like this plays a pivotal role in holding corporations accountable for their accountability and practices. Investors adversely affected by financial misstatements can potentially regain their losses through such legal proceedings. Don’t wait until it’s too late; ensure your voice and interests are represented in the ADMA Biologics case today.